{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:09:50Z","timestamp":1767773390657,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006736","name":"Universitetssjukhuset \u00d6rebro","doi-asserted-by":"publisher","award":["OLL-502241"],"award-info":[{"award-number":["OLL-502241"]}],"id":[{"id":"10.13039\/501100006736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s10096-017-2966-z","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T02:51:50Z","timestamp":1490151110000},"page":"1549-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections"],"prefix":"10.1007","volume":"36","author":[{"given":"C.","family":"Littorin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hellmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5.","family":"Nilsdotter-Augustinsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"S\u00f6derquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"2966_CR1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/678600","volume":"35","author":"V Lindgren","year":"2014","unstructured":"Lindgren V, Gordon M, Wretenberg P, K\u00e4rrholm J, Garellick G (2014) Deep infection after total hip replacement: a method for national incidence surveillance. Infect Control Hosp Epidemiol 35:1491\u20131496","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2966_CR2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMra040181","volume":"351","author":"W Zimmerli","year":"2004","unstructured":"Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. N Engl J Med 351:1645\u20131654","journal-title":"N Engl J Med"},{"key":"2966_CR3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","volume":"56","author":"DR Osmon","year":"2013","unstructured":"Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56:e1\u2013e25","journal-title":"Clin Infect Dis"},{"key":"2966_CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/joim.12233","volume":"276","author":"W Zimmerli","year":"2014","unstructured":"Zimmerli W (2014) Clinical presentation and treatment of orthopaedic implant-associated infection. J Intern Med 276:111\u2013119","journal-title":"J Intern Med"},{"key":"2966_CR5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1469-0691.2008.02663.x","volume":"15","author":"B Hellmark","year":"2009","unstructured":"Hellmark B, Unemo M, Nilsdotter-Augustinsson \u00c5, S\u00f6derquist B (2009) Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect 15:238\u2013244","journal-title":"Clin Microbiol Infect"},{"key":"2966_CR6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/AAC.00775-08","volume":"53","author":"D Baldoni","year":"2009","unstructured":"Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A (2009) Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother 53:1142\u20131148","journal-title":"Antimicrob Agents Chemother"},{"key":"2966_CR7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.clinthera.2006.08.001","volume":"28","author":"E Senneville","year":"2006","unstructured":"Senneville E, Legout L, Valette M, Yazdanpanah Y, Beltrand E, Caillaux M et al (2006) Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 28:1155\u20131163","journal-title":"Clin Ther"},{"key":"2966_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40121-014-0032-z","volume":"3","author":"L Morata","year":"2014","unstructured":"Morata L, Senneville E, Bernard L, Nguyen S, Buzel\u00e9 R, Druon J et al (2014) A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther 3:235\u2013243. doi:\n10.1007\/s40121-014-0032-z","journal-title":"Infect Dis Ther"},{"key":"2966_CR9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2016.01.008","volume":"85","author":"SM Schmidt-Malan","year":"2016","unstructured":"Schmidt-Malan SM, Greenwood Quaintance KE, Karau MJ, Patel R (2016) In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis 85:77\u201379","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2966_CR10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2014.08.011","volume":"81","author":"DF Sahm","year":"2015","unstructured":"Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ et al (2015) Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 81:112\u2013118","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2966_CR11","first-page":"1","volume":"SQ1","author":"RN Jones","year":"2009","unstructured":"Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M (2009) TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J Antimicrob Chemother SQ1:1\u20135","journal-title":"J Antimicrob Chemother"},{"key":"2966_CR12","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/AAC.00228-09","volume":"53","author":"R Schaadt","year":"2009","unstructured":"Schaadt R, Sweeney D, Shinabarger D, Zurenko G (2009) In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 53:3236\u20133239","journal-title":"Antimicrob Agents Chemother"},{"key":"2966_CR13","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/AAC.01653-09","volume":"54","author":"C Betriu","year":"2010","unstructured":"Betriu C, Morales G, Rodr\u00edguez-Avial I, Culebras E, G\u00f3mez M, L\u00f3pez-Fabal F et al (2010) Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother 54:2212\u20132215","journal-title":"Antimicrob Agents Chemother"},{"key":"2966_CR14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/AAC.01569-09","volume":"54","author":"SD Brown","year":"2010","unstructured":"Brown SD, Traczewski MM (2010) Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 54:2063\u20132069","journal-title":"Antimicrob Agents Chemother"},{"key":"2966_CR15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10096-013-2025-3","volume":"33","author":"S Tevell","year":"2014","unstructured":"Tevell S, Claesson C, Hellmark B, S\u00f6derquist B, Nilsdotter-Augustinsson \u00c5 (2014) Heterogeneous glycopeptide intermediate Staphylococcus epidermidis isolated from prosthetic joint infections. Eur J Clin Microbiol Infect Dis 33:911\u2013917","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2966_CR16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","volume":"34","author":"SD Flanagan","year":"2014","unstructured":"Flanagan SD, Bien PA, Mu\u00f1oz KA, Minassian SL, Prokocimer PG (2014) Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 34:240\u2013250","journal-title":"Pharmacotherapy"},{"key":"2966_CR17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","volume":"75","author":"GG Zhanel","year":"2015","unstructured":"Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F et al (2015) Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 75:253\u2013270","journal-title":"Drugs"},{"key":"2966_CR18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","volume":"59","author":"S Flanagan","year":"2015","unstructured":"Flanagan S, McKee EE, Das D, Tulkens PM, Hosako H, Fiedler-Kelly J et al (2015) Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother 59:178\u2013185","journal-title":"Antimicrob Agents Chemother"},{"key":"2966_CR19","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1128\/AAC.03423-14","volume":"58","author":"S Flanagan","year":"2014","unstructured":"Flanagan S, Passarell J, Lu Q, Fiedler-Kelly J, Ludwig E, Prokocimer P (2014) Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother 58:6462\u20136470","journal-title":"Antimicrob Agents Chemother"},{"key":"2966_CR20","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/jac\/dkw206","volume":"71","author":"TP Lodise","year":"2016","unstructured":"Lodise TP, Bidell MR, Flanagan SD, Zasowski EJ, Minassian SL, Prokocimer P (2016) Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. J Antimicrob Chemother 71:2553\u20132558","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-017-2966-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-2966-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-2966-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T07:38:10Z","timestamp":1502437090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-017-2966-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["2966"],"URL":"https:\/\/doi.org\/10.1007\/s10096-017-2966-z","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}